Methods for identification of bone anabolic agents
The present invention is related to methods for identifying bone anabolic agents and factors, identifying pathways that promote proliferation of osteoblasts for bone growth and/or repair, and for identifying new therapeutic targets for treatments for osteoporosis and other bone degenerative disorders characterized by osteopenia.
1. A method for identifying a compound capable of inducing bone growth, which method comprises the steps of:
providing a Sox2 deficient cell having a Sox2 defect;
contacting said cell with said compound; and
determining if said compound rescued the Sox2 defect following said contacting step, wherein said compound is useful for inducing bone growth if it rescued the Sox 2 defect.
2. A method for identifying a compound capable of inducing bone growth, which method comprises the steps of:
quantifying at least one Sox2 responsive gene expression level in a wild-type cell;
providing a Sox2 deficient cell having a Sox2 defect;
contacting said Sox2 deficient cell with said compound;
quantifying the gene expression level of at least one Sox2 responsive gene in said Sox2 deficient cell following said contacting step; and
comparing the gene expression level of said Sox2 responsive gene to the gene expression level of said Sox2 responsive gene obtained from a wild-type cell; wherein said compound is capable of inducing bone growth if the gene expression level of said Sox2 deficient cell is substantially similar to the gene expression level of said wild-type cell.
3. The method of claim 1 , wherein said cell is an osteoblast.
4. The method of claim 1 , wherein said cell is a mesenchymal stem cell.
5. The method of claim 1 , wherein said Sox2 defect is characterized by an inability of said cell to proliferate.
6. The method of claim 1 , wherein said Sox2 defect is characterized by an inability of said cell to survive in culture.
7. The method of claim 1 , wherein said Sox2 defect is characterized by an inability of said cell to self-renew.
8. The method of claim 1 , wherein said Sox2 defect is characterized by an inability of said cell to differentiate into an osteoblast.
9. The method of claim 2 , wherein the gene expression level of said at least one Sox2 responsive gene is determined by polymerase chain reaction (PCR).
10. The method of claim 2 , wherein the Sox2 deficient cell is an osteoblast.
11. The method of claim 2 , wherein the Sox2 deficient cell is a mesenchymal stem cell.
12. The method of claim 2 , wherein said Sox2 defect is characterized by an inability of said cell to proliferate.
13. The method of claim 2 , wherein said Sox2 defect is characterized by an inability of said cell to survive in culture.
14. The method of claim 2 , wherein said Sox2 defect is characterized by an inability of said cell to self-renew.
15. The method of claim 2 , wherein said Sox2 defect is characterized by an inability of said cell to differentiate into an osteoblast.
16. The method of claim 1 wherein said assay contains a negative control.
17. The method of claim 16 wherein said assay contains a positive control.
18. The method of claim 2 wherein said assay contains a negative control.
19. The method of claim 18 wherein said assay contains a positive control.